Pfizer Corporation Austria Ges. m.b.H.

Floridsdorfer Hauptstr.1
1210 Wien
Austria

Contact

About Pfizer

Helping people to a healthier and longer life with a higher quality of life is the aim of Pfizer . Under the motto " Working together for a healthier world TM ", more than 97,000 employees worldwide are working to achieve this goal. They are researching, developing and marketing drugs and vaccines to treat or prevent some of the most menacing diseases of our time. The focus is on cancer, inflammatory diseases, pain,cardiovascular diseases as well as disorders of the central nervous system. In developing new treatment options , Pfizer is focusing on the great potential of biotherapeutics and targeted treatments.

Product portfolio of Pfizer

Product portfolio

Show all

News about Pfizer

25-Oct-2022 | business & finance

Anokion Announces $35 Million Equity Investment from Pfizer

Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development

Read news

20-Jun-2022 | business & finance

Pfizer will invest €90.5 million in Valneva

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Read news

30-Sep-2021 | research and development

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program

The mRNA technology could to improve upon the efficacy of current flu vaccines

Read news

24-Aug-2021 | research and development

FDA Approves First COVID-19 Vaccine

The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now ...

Read news

03-Mar-2021 | business & finance

Iktos Announces Collaboration With Pfizer in AI for Drug Design

“We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”

Read news

10-Nov-2020 | research and development

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

Read news